288 related articles for article (PubMed ID: 28148635)
1. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Steinmiller KC; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stuve O; Arnold DL; Wener MH; Georges GE; Wundes A; Kraft GH; Bowen JD
Neurology; 2017 Feb; 88(9):842-852. PubMed ID: 28148635
[TBL] [Abstract][Full Text] [Related]
2. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
[TBL] [Abstract][Full Text] [Related]
3. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis.
Lee H; Nakamura K; Narayanan S; Brown RA; Nash RA; Griffith LM; Steinmiller KC; Devine SM; Hutton GJ; Popat U; Racke MK; Georges GE; Bowen JD; Arnold DL
Mult Scler Relat Disord; 2021 Sep; 54():103149. PubMed ID: 34284316
[TBL] [Abstract][Full Text] [Related]
4. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
[TBL] [Abstract][Full Text] [Related]
5. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
Nash RA; Bowen JD; McSweeney PA; Pavletic SZ; Maravilla KR; Park MS; Storek J; Sullivan KM; Al-Omaishi J; Corboy JR; DiPersio J; Georges GE; Gooley TA; Holmberg LA; LeMaistre CF; Ryan K; Openshaw H; Sunderhaus J; Storb R; Zunt J; Kraft GH
Blood; 2003 Oct; 102(7):2364-72. PubMed ID: 12763935
[TBL] [Abstract][Full Text] [Related]
6. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
7. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
8. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
[TBL] [Abstract][Full Text] [Related]
10. [The role and place of high-dose immunosuppressive therapy and autologous transplantation of hematopoietic stem cells for autoimmune diseases].
Makarov SV; Rossiev VA; Mishchenko OV; Kozlov VA; Semagina OV; Alexandrova IY; Grishina GV; Minaev YL
Ter Arkh; 2016; 88(1):53-59. PubMed ID: 26978610
[TBL] [Abstract][Full Text] [Related]
11. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.
Bowen JD; Kraft GH; Wundes A; Guan Q; Maravilla KR; Gooley TA; McSweeney PA; Pavletic SZ; Openshaw H; Storb R; Wener M; McLaughlin BA; Henstorf GR; Nash RA
Bone Marrow Transplant; 2012 Jul; 47(7):946-51. PubMed ID: 22056644
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
13. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis.
Shevchenko YL; Novik AA; Kuznetsov AN; Afanasiev BV; Lisukov IA; Kozlov VA; Rykavicin OA; Ionova TI; Melnichenko VY; Fedorenko DA; Kulagin AD; Shamanski SV; Ivanov RA; Gorodokin G
Exp Hematol; 2008 Aug; 36(8):922-8. PubMed ID: 18468768
[TBL] [Abstract][Full Text] [Related]
14. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
15. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
[TBL] [Abstract][Full Text] [Related]
17. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
18. Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.
Ruiz-Argüelles GJ; Olivares-Gazca JC; Olivares-Gazca M; Leon-Peña AA; Murrieta-Alvarez I; Cantero-Fortiz Y; Gomez-Cruz GB; Ruiz-Argüelles A; Priesca-Marin M; Ruiz-Delgado GJ
Clin Exp Immunol; 2019 Dec; 198(3):351-358. PubMed ID: 31394007
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab for multiple sclerosis.
Riera R; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
[TBL] [Abstract][Full Text] [Related]
20. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
Burman J; Iacobaeus E; Svenningsson A; Lycke J; Gunnarsson M; Nilsson P; Vrethem M; Fredrikson S; Martin C; Sandstedt A; Uggla B; Lenhoff S; Johansson JE; Isaksson C; Hägglund H; Carlson K; Fagius J
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1116-21. PubMed ID: 24554104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
